# **MEDICATIONS**

#### **TABLE OF CONTENTS**

| ACTIVATED CHARCOAL                               | 4        |
|--|----------|
| ADENOSINE (Adenocard)                            | 5        |
| ALBUTEROL (Proventil, Ventolin)                  | 6        |
| AMIODARONE (Pacerone)                            | 7        |
| AMYL NITRITE                                     | 8        |
| ASPIRIN (Acetylsalicylic Acid)                   | 9        |
| ATIVAN (Lorazepam)                               | 10       |
| ATROPINE   | 11       |
| ATROVENT (Ipratropium Bromide)                   | 12       |
| CALCIUM GLUCONATE                                | 13       |
| CAPTOPRIL (Capoten)                              | 14       |
| DEXAMETHASONE (Decadron)                         | 15       |
| DEXTROSE (Glucose)                               | 16       |
| DIPHENHYDRAMINE (Benadryl)                       | 17       |
| DOPAMINE (Intropin)                              | 18       |
| DROPERIDOL (Inapsine)                            | 19       |
| DUONEB (Albuterol/Atrovent mix)                  | 20       |
| ECALLANTIDE (Kalbitor)                           | 21       |
| EPINEPHRINE 1:1,000                              | 22       |
| EPINEPHRINE 1:10,000                             | 23       |
| ETOMIDATE (Amidate)                              | 24       |
| FENTANYL (Sublimaze)                             | 25       |
| FUROSEMIDE (Lasix)<br>GLUCAGON                   | 26       |
|  | 27<br>28 |
| HALOPERIDOL LACTATE (Haldol)                     | 20       |
| HYDROXYCOBALAMIN (Cyanokit)<br>IV SOLUTION (BSS) | 30       |
| KETAMINE (Ketalar)                               | 30       |
| KETOROLAC (Toradol)                              | 33       |
| LIDOCAINE (Xylocaine)                            | 35       |
| HIXSON LIDOCAINE CHART                           | 36       |
| MAGNESIUM SULFATE                                | 37       |
| MIDAZOLAM (Versed)                               | 38       |
| MORPHINE SULFATE                                 | 39       |
| NALOXONE (Narcan)                                | 40       |
| NITROGLYCERIN                                    | 40       |
| NOREPINEPHRINE (Levophed)                        | 42       |
| OLANZAPINE (Zyprexa)                             | 43       |
| OXYGEN   | 44       |
| OXYGEN FLOW CHART                                | 45       |
| OXYMETAZOLINE HYDROCHLORIDE (Afrin)              | 46       |
| OXYTOCIN (Pitocin)                               | 47       |
| ROCURONIUM (Zemuron)                             | 48       |
| SODIUM BICARBONATE                               | 49       |
| SUCCINYLCHOLINE (Anectine)                       | 50       |
| THIAMINE   | 51       |
| TRANEXAMIC ACID                                  | 52       |

#### VECURONIUM (Norcuron) ZOFRAN (Ondansetron) 2022 MEDICATION REVISIONS

53 54 55

#### **ACTIVATED CHARCOAL**

| Activated Charcoal | [EMT/AEMT/EMT-I/RN/EMT-P]<br>OLMC Approval Required  |
|--------------------|--|
| Class:             | Absorbent  |
| Actions:           | Absorbs toxins by binding to them to prevent GI absorption.  |
| Indications:       | Adsorbent used in overdoses and poisonings<br>eg. Acetaminophen [Tylenol] ingestion  |
| Contraindications: | <ul> <li>Absolute (may be harmful):</li> <li>1. Vomiting/Inability to protect airway</li> <li>2. Petroleum product ingestion</li> <li>3. Corrosive ingestion (mineral acids, strong bases)</li> <li>Relative (unlikely to be effective):</li> <li>1. Toxic Alcohol ingestion         (ethanol, methanol, isopropanol, ethylene glycol)</li> <li>2. Lithium ingestion</li> <li>3. Metals ingestion (iron, lead, mercury, etc.)</li> </ul> |
| Precautions:       | 1. Patient must be alert and able to avoid aspiration.   |
| Side Effects:      | Vomiting, aspiration, constipation, bowel obstruction  |
| Dosage:            | <i>Adults:</i> 50 gm PO<br><i>Pediatric:</i> 1 gm/kg PO, NMT 50 gm   |
| Supply:            | 25 gm bottles  |
| Comments:          | <ol> <li>Activated Charcoal interferes with some antidotes.</li> <li>It is unlikely to be useful unless given in the first hour after<br/>ingestion.</li> <li>Shake vigorously before using.</li> </ol>  |

#### ADENOSINE (Adenocard)

| Adenosine (Adenoc  | card) [EMT-P   |
|--------------------|--|
| Class:             | Anti-arrhythmic  |
| Actions:           | Slows conduction through the AV node.  |
| Indications:       | <ol> <li>Stable Narrow-QRS Tachycardia refractory to vagal<br/>maneuvers</li> <li>Unstable Narrow-QRS Tachycardia if IV access immediately<br/>available:         <ul> <li>a. Rate ≥ 150/min. (adult), ≥ 220 (children)</li> <li>b. Regular rhythm</li> <li>c. QRS &lt; 0.12 seconds</li> </ul> </li> </ol>  |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Wide QRS (&gt; 0.12 seconds) Tachycardia</li> <li>Second or Third degree heart block</li> <li>Sick Sinus Syndrome</li> </ol>  |
| Precautions        | In the presence of carbamazepine (Tegretol), may produce<br>higher degrees of heart block or may develop asystole (1%)<br>which can last for 3 days  |
| Side Effects:      | Transient asystole, AV block, PVCs, Hypotension  |
| Dosage:            | <ul> <li>Adults: 6 mg (2 ml) IV/IO over 1-2 sec. If not effective after 2 min., administer:</li> <li>12 mg [4 ml] IV/ IO.</li> <li>Follow each dose with a 20 ml NS IV flush.</li> <li>Pediatric: 0.1 mg/kg IV/IO over 1-2 sec. If not effective after 2 minutes, administer:</li> <li>0.2 mg/kg. NMT 12 mg.</li> <li>Follow each dose with a 5 ml NS IV flush.</li> </ul>   |
| Supply:            | 6mg/2ml Prefilled syringe<br>12mg/4ml Prefilled syringe  |
| Comments:          | <ol> <li>Does not convert atrial flutter, atrial fibrillation, or ventricular<br/>tachycardia. May cause temporary slowing.</li> <li>Adenosine is antagonized by methylxanthines (such as<br/>caffeine, theophyline) May require larger dose to treat.</li> <li>Adenosine effects are potentiated by dipryidomole and will<br/>require smaller doses to treat.</li> <li>Use injection port closest to body and follow immediately<br/>with flush.</li> </ol> |

# ALBUTEROL (Proventil, Ventolin)

| Albuterol (Proventil | , Ventolin)  | [EMT/AEMT/EMT-I/RN/EMT-P]  |
|----------------------|--|--|
| Class:               | Sympathomimetic (β2  | selective)   |
| Actions:             | Bronchodilation  |  |
| Indications:         | Wheezing and respirat<br>COPD, anaphylaxis<br>Hyperkalemia                                 | ory distress due to asthma, emphysema,   |
| Contraindications:   | 2. Avoid in the followin<br>a. Chest pain  | ng unless symptoms are severe:<br>min. (adults) or > 180/min. (children)         |
| Precautions:         | Risk of transient hypok  | alemia   |
| Side Effects:        | Tachycardia, hypertens<br>headache   | sion, arrhythmias, tremor, anxiety,  |
| Dosage:              | <i>Adults:</i> 1 unit dose, ne<br><i>Pediatric:</i> 1 unit dose,<br>May repeat in 10 minut |  |
| Supply:              | Bottle of 0.083% soluti  | on contains 2.5 mg in 3 ml.  |
| Comments:            | < 4 yrs old: nebulizer h   | M [until nebulizer mists]<br>eld under the face<br>rith mouth piece or face mask |

#### AMIODARONE (Pacerone)

| Amiodarone (Pacer  | one) [EMT-I/RN  | /EMT-P]                        |
|--------------------|---|--------------------------------|
| Class:             | Anti-arrhythmic   |                                |
| Actions:           | <ol> <li>Depresses automaticity of SA node.</li> <li>Slows conduction &amp; increases refractoriness of the A</li> <li>Increases Atrial &amp; Ventricular refractoriness</li> </ol>   | V node.                        |
| Indications:       | Pulseless VF / VT, V-tach with pulse, Wide complex Tachycardia  |                                |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Sinus node dysfunction, 2°/3° AV block, bradycardia,<br/>cardiogenic shock</li> </ol>  |                                |
| Precautions:       | May cause hyperthyroidism   |                                |
| Side Effects:      | May produce vasodilation, hypotension, a prolonged QT interval, and a negative inotropic effect   |                                |
| Dosage:            | Adults: 1. V-fib / Pulseless V-tach: 300 mg IV/IO may re-<br>once in 3 – 5 min at 150 mg IV/IO.<br>If pt converts administer maintenance drip at 1m<br>2. V-tach with pulse / Wide complex Tachycardia<br>150mg in 50ml LR or NS. Rapid infusion of 15 m<br>over 10 min. may repeat 150mg rapid infusion in<br>min. If pt converts administer maintenance drip a<br>min | ng/min<br>a:<br>ng/min<br>n 10 |
|                    | <ul> <li>Pediatric: 1. V-fib / Pulseless V-tach: 5 mg/kg IV/IO may repeat once in 3 – 5 min. at 2.5 mg/kg IV/IO</li> <li>2. V-tach with pulse / Wide complex Tachycardia</li> <li>2.5 mg/kg IV/IO over 10 min.</li> </ul>   |                                |
| Supply:            | 50mg in 3 ml preload 150mg in 3 ml vial   |                                |
| Comments:          | <i>Maintenance Drip</i> : Mix 150mg in 50ml LR or NS and adr<br>1mg/min on micro drip set. (Approx 20 gtts/min)   | ninister                       |
|                    | <i>Rapid Infusion</i> : Mix 150mg in 50ml LR or NS and admin 15 mg/min infusion with <u>macro</u> drip set. (Approx. 75gtts/  |                                |
|                    | <i>Pediatric Infusion:</i> Mix pediatric dose (2.5 mg/kg) with 50 NS and infuse over 10 min. May mix pediatric dose with of NS in solu-set for patients less than 25kg.   |                                |

#### AMYL NITRITE

| Amyl Nitrite        | [EMT-P]  |
|---------------------|--|
| Class:              | Inhalant   |
| Actions:            | Amyl Nitrate has affinity for cyanide ions; reacts with hemoglobin to form methemoglobin.  |
| Indications:        | Cyanide or hydrocyanic poisoning   |
| Contraindications:  | <ol> <li>Hypersensitivity/allergy to organic nitrites</li> <li>Recent (last 24 hr) Sildenafil (Viagra) or other<br/>phosphodiesterase-5 inhibitor use.</li> <li>Severe anemia</li> </ol> |
| Precautions:        | May cause postural hypotension. Patient should be sitting down during and immediately after inhaling.  |
| Side Effects:       | Headache   |
| Adults & Pediatric: | <i>Adults &amp; Pediatric:</i> Breathe Amyl Nitrate vapors for 30 seconds, then breathe Oxygen for 30 seconds repeat this procedure continuously   |
| Supply:             | 0.3 mL capsules  |
| Comments:           | Protect yourself from exposure to cyanide sources.<br>DO NOT BECOME A VICTIM YOURSELF.   |

#### ASPIRIN (Acetylsalicylic Acid)

| Acetylsalicylic Acid | (Aspirin) [EMR/EMT/AEMT/EMT-I/RN/EMT-P]   |  |
|----------------------|---|--|
| Class:               | Analgesic, antipyretic  |  |
| Actions:             | Blocks platelet aggregation   |  |
| Indications:         | Chest pain suggestive of AMI  |  |
| Contraindications:   | <ol> <li>Allergy to aspirin or aspirin induced asthma.</li> <li>History of active bleeding disorder (i.e., hemophilia).</li> <li>Current GI bleeding.</li> <li>Suspected aortic dissection.</li> <li>Not to be used in suspected CVA patients until intracranial<br/>hemorrhage has been ruled out by CT</li> </ol> |  |
| Precautions:         | Caution in patients with known active peptic ulcer.   |  |
| Side Effects:        | Urticaria, angioedema, bronchospasm, anaphylactic shock, nausea, vomiting, heartburn, GI bleed and prolonged bleeding   |  |
| Dosage:              | <i>Adults:</i> 4 chewable baby aspirin (81 mg each) PO<br><i>Pediatric:</i> <b>Not Indicated</b>  |  |
| Supply:              | 81 mg tablets   |  |
| Comments:            | Do not use in pediatric patients with chicken pox or influenza<br>like illness due to association with increased risk of Reye's<br>Syndrome   |  |

# ATIVAN (Lorazepam)

| Ativan (Lorazepam) | [EMT-P]  |
|--------------------|--|
| Class:             | Benzodiazepine   |
| Actions:           | Anti-convulsant, tranquilizer and skeletal muscle relaxant   |
| Indications:       | <ol> <li>Seizures/status epilepticus</li> <li>As an amnesic / anxiolytic prior to cardioversion</li> <li>Chemical restraint</li> </ol>   |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Severe respiratory insufficiency (unless mechanically<br/>ventilated)</li> <li>CNS depression</li> </ol>  |
| Precautions:       | <ol> <li>Inadvertent intra-arterial injection may produce<br/>arteriospasm, potentially leading to amputation.</li> <li>Use cautiously and monitor closely in patients with sleep<br/>apnea.</li> </ol>                                      |
| Side Effects:      | <ol> <li>Drowsiness, dizziness, fatigue and ataxia.</li> <li>Most likely to produce respiratory depression in patients who<br/>have taken other depressant drugs, especially alcohol and<br/>barbiturates, or when given rapidly.</li> </ol> |
| Dosage:            | <i>Adults:</i> 0.5-2.0 mg IV/IO/IM<br><i>Pediatric:</i> 0.1mg/kg IV/IO/IM<br>May repeat in 10 min NMT 4.0 mg.  |
| Supply:            | 2 mg/ml Carpuject / Vial 2 mg/ml – 2 ml Vial   |
| Comments:          | <ol> <li>If given IM, do not dilute.</li> <li>Dilute 1:1 for IV/IO.</li> <li>Consider rectal administration (if unable to administer IV) in<br/>seizing children. Contact Medical Control hospital prior to<br/>doing so.</li> </ol>         |

#### ATROPINE

| Atropine Sulfate                               | [EMT*/AEMT*/EMT-I/RN/EMT-P]  |  |
|--|--|--|
| Class:   | Parasympatholytic (anticholinergic)  |  |
| Actions:                                       | Blocks acetylcholine receptors (decreases vagal tone thus increasing heart rate)   |  |
| Indications:                                   | <ol> <li>Narrow-QRS (&lt; 0.12 sec) bradycardia with systolic BP &lt; 90,<br/>decreased LOC, chest pain, or PVC's</li> <li>*Severe organophosphate (insecticide) poisoning</li> </ol>  |  |
| Contraindications:                             | Wide-QRS (≥ 0.12 sec) Bradycardia  |  |
| Precautions:                                   | Glaucoma   |  |
| Side Effects:                                  | Tachycardia, chest pain, blurred vision, headache, dry mouth, flushing, urinary retention  |  |
| <b>Dosage:</b><br>Bradycardia                  | Adults: 0.5 - 1 mg IV/IO q 5 min, NMT 3 mg<br>(double dose for ETT)<br>Pediatric: 0.02 mg/kg IV/IO or 0.04 mg/kg ET<br>(Avoid age < 1 month).<br>MINIMUM DOSE: 0.1 mg<br>MAXIMUM TOTAL DOSE (child): 1.0 mg(0.04 mg/kg)<br>MAXIMUM TOTAL DOSE (adolescent): 2.0 mg (0.04 mg/ kg)   |  |
| <b>Dosage:</b><br>Organophosphate<br>Poisoning | Adults: 1 - 2 mg IV/IO<br>Pediatric: 0.05 mg/kg IV/IO NMT 1mg/dose<br>Repeat q 5 - 10 min until muscarinic symptoms disappear or<br>atropine toxicity appears.   |  |
| Supply:  | Prefilled syringe: contains 1 mg (10 ml)<br>Vial: 20 ml – 0.4 mg/ml  |  |
| Comments:                                      | <ol> <li>Use cautiously in patients with chest pain</li> <li>*EMT/AEMT's are only authorized to give atropine in<br/>auto-injector for organophosphate poisoning.</li> <li>Severe organophosphate poisoning may require double<br/>doses if:         <ul> <li>a. Systolic BP &lt; 90</li> <li>b. Decreased LOC</li> <li>c. Respiratory distress</li> <li>d. Excessive oral secretions</li> <li>e. Pulse &lt; 60</li> </ul> </li> </ol> |  |

# ATROVENT (Ipratropium Bromide)

| Atrovent (ipratropiu | ım bromide)  | [EMT/AEMT/EMT-I/RN/EMT-P]                                      |
|----------------------|--|--|
| Class:               | Anticholinergic  |  |
| Actions:             | Inhibits interaction of acetyle bronchial smooth muscle re | choline at receptor sites of the sulting in bronchial dilation |
| Indications:         | For Relief of Bronchospasm                                 | is in those with COPD  |
| Contraindications:   | Hypersensitivity/allergy                                   |  |
| Precautions:         | Narrow angle glaucoma,                                     |  |
| Side Effects:        | N/V, Dry mouth, cramps, an worsening of Bronchospasn       | xiety, dizziness, H/A, cough ,<br>ns                           |
| Dosage:              | Adults & Pediatric: 0.5 mg n                               | ebulized mixed with albuterol dose.                            |
| Supply:              | 2.5 ml of solution (0.5 mg) p                              | er unit dose for nebulization                                  |
| Comments:            | subsequent Neb treatments                                  | ment for pediatric patients if                                 |

#### CALCIUM GLUCONATE

| Calcium Gluconate             | [EMT-P]   |
|-------------------------------|---|
| Class:                        | Membrane stabilizer and antidote  |
| Actions:                      | <ol> <li>Calcium is the most common cation in the human body and<br/>the majority of the body stores are located in bone.</li> <li>It is critical in many different cellular processes and is<br/>essential for the functional integrity of muscle (skeletal,<br/>smooth and cardiac) and nervous tissues.</li> </ol>   |
| Indications:                  | <ol> <li>Hyperkalemia (suspected hyperkalemia in PEA/Asytole)</li> <li>Calcium channel blocker overdoses</li> <li>Hydrofluoric acid poisoning</li> <li>latrogenic magnesium intoxication</li> </ol>   |
| Contraindications:            | <ol> <li>Hypersensitivity/allergy</li> <li>Digoxin Poisoning.</li> <li>Hypercalcemia</li> </ol>   |
| Precautions:                  | Avoid use with patients who are on Digoxin since calcium can<br>augment the positive inotropic and negative chronotropic effects<br>of digitalis preparations.  |
| Side Effects:                 | <ul> <li>Rapid IV administration can cause:</li> <li>1. Bradycardia</li> <li>2. Vasodilatation</li> <li>3. Hypotension</li> <li>4. Syncope</li> <li>5. Local irritation &amp; burning</li> </ul>  |
| Dosage: PEA/<br>Asystole      | <i>Adults:</i> 3 gm (30 ml) IV/IO over 10 mins<br><i>Pediatric: 50 mg/kg</i> (0.5 ml/kg) IV/IO over 10 mins   |
| Dosage: All other indications | Adults: 1 gm (10 ml) IV/IO over 10 mins<br>Pediatric: 10 mg/kg (0.1 ml/kg) IV/IO over 10 mins   |
| Supply:                       | 1 gm in 10 ml   |
| Comments:                     | <ol> <li>Administer slowly (no faster than 2.0 ml/min) and stop if the patient complains of pain.</li> <li>Inject using a small needle in large vein and do not mix with bicarbonate.</li> <li>As a membrane stabilizer in suspected hyperkalemia, it reverses EKG changes pending correction of the extracellular potassium concentration. Suspect hyperkalemia in patient with wide complex arrhythmia or tall peaked T-waves and Hx of renal failure.</li> </ol> |

# CAPTOPRIL (Capoten)

| Captopril (Capoten) | [EMT-P]   |
|---------------------|---|
| Class:              | Angiotensin Conversion Inhibitor (ACE-I)  |
| Actions:            | Inhibits angioensin-II mediated vasoconstriction<br>Lowers blood pressure   |
| Indications:        | <ol> <li>Flash pulmonary Edema</li> <li>CHF</li> </ol>  |
| Contraindications:  | Hypersensitivity/allergy to any ACE-I   |
| Precautions:        | Impaired renal function<br>Auto-immune disease (Lupus, etc.)<br>Elderly may be more sensitive to drug's hypotensive effects.  |
| Side Effects:       | Tachycardia, hypotension, angina.<br>Nausea, vomiting, abdominal pain.<br>Allergic Reaction may be rash, swelling of tongue, angioedema<br>of the face and extremities.   |
| Dosage:             | Adults: 12.5 mg sublingual<br>(May dampen with small amount of sterile water or<br>normal saline to help tablet to dissolve.)   |
| Supply:             | 12.5 mg white tab.  |
| Comments:           | <ol> <li>Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.</li> <li>Decreases peripheral arterial resistance so there is reduced sodium and water retention and lowers blood pressure.</li> <li>Onset occurs in 15-30 minutes. Duration is 6-12 hours.</li> </ol> |

#### **DEXAMETHASONE** (Decadron)

| Dexamethasone (De  | ecadron) [EMT-P   |
|--------------------|---|
| Class:             | Corticosteroid  |
| Actions:           | Anti-inflammatory   |
| Indications:       | <ol> <li>Moderate to severe asthma/COPD</li> <li>Severe allergic reactions</li> <li>Croup</li> <li>Adrenal insufficiency</li> </ol>   |
| Contraindications: | Systemic fungal infection   |
| Precautions:       | Pregnancy, peptic ulcer disease<br>Hypersensitivity/allergy   |
| Side Effects:      | <ol> <li>Hyperglycemia</li> <li>Hypertension</li> <li>Anxiety/psychosis</li> <li>Adrenal suppression</li> <li>N/V, headache or dizziness</li> </ol>   |
| Dosage:            | Adults (>40 lb): 10 mg IV/IO/IM/PO<br>Pediatric (< 40 lb) dose:<br>Airway Emergencies: 0.6 mg/kg IV/IO/IM/PO NMT 10<br>mg<br>Adrenal Insufficiency: 0.05 mg/kg IV/IO/IM   |
| Supply:            | 10 mg/1 ml Vial   |
| Comments:          | Dexamethasone is a synthetic steroid that suppresses acute<br>and chronic inflammation. In addition, it potentiates vascular<br>smooth muscle relaxation by beta-adrenergic agonists and may<br>alter airway hyperactivity. |

#### DEXTROSE (Glucose)

| DEXTROSE<br>(Glucose)             | [EMR/EMT/AEMT/EMT-I/RN/EMT-P]   |  |  |  |  |  |
|-----------------------------------|---|--|--|--|--|--|
| Class:                            | Carbohydrate  |  |  |  |  |  |
| Actions:                          | Elevates blood glucose level  |  |  |  |  |  |
| Indications:                      | <ul> <li>1.Symptomatic hypoglycemia <ul> <li>a.BGL &lt; 60 mg/dl</li> <li>b.BGL &lt; 60 mg/dl in Child (1 year to puberty)</li> <li>c.BGL &lt; 40 mg/dl in Infant (Birth to 1 year)</li> </ul> </li> <li>2.Consider in patients when unable to assess BGL or if: <ul> <li>a.GCS ≤ 12</li> <li>b.Seizures lasting ≥ 3 minutes</li> </ul> </li> </ul> |  |  |  |  |  |
| Contraindications:                | No absolute contraindications.  |  |  |  |  |  |
| Precautions:                      | Relative contraindications are intracranial hemorrhage and stroke.  |  |  |  |  |  |
| Side Effects:                     | Tissue injury if infiltration occurs.<br>Aspirate blood before and during injection.  |  |  |  |  |  |
| Dosage:<br>EMR/EMT                | <i>Adults:</i> 15 - 25 g orally if patient can protect airway <i>Pediatric:</i> 0.5 g/kg orally if patient can protect airway   |  |  |  |  |  |
| Dosage:<br>AEMT/EMT-I/RN<br>EMT-P | <ul> <li>Adults: D50: 10-50 mL (5 - 25 g) IV or IO; Consider diluting 1:5 to decrease risk of tissue necrosis.</li> <li>Any age: D10: 5 ml/kg (0.5 gm/kg) IV/IO up to 25g</li> <li>Any age: D5: 10 ml/kg (0.5 gm/kg) IV/IO up to 25g</li> <li>May repeat 0.5 gm/kg if pt remains hypoglycemic</li> </ul>  |  |  |  |  |  |
| Supply:                           | 25 g per tube; Glutose: 15 gm tube<br>Prefilled syringe contains 25 gm (50 ml)<br>D50 contains 5 g glucose per 10 ml (50% glucose)<br>D10 contains 5 g glucose per 50 ml (10% glucose)<br>D5 contains 2.5 g glucose per 50 ml (5% glucose)  |  |  |  |  |  |
| Comments:                         | Perform rapid glucose determination before administration.<br>Maximum single dose: 25 g dextrose = 500ml D5 = 250 ml D10<br>= 50 ml D50.<br>Recheck BGL before administering additional glucose.<br>May repeat every 3-5 minutes as needed for persistent<br>hypoglycemia.<br>Effect is delayed in elderly people with poor circulation.            |  |  |  |  |  |

#### DIPHENHYDRAMINE (Benadryl)

| Diphenhydramine H<br>(Benadryl) | ICL [EMT-I/RN/EMT-P]  |
|---------------------------------|---|
| Class:                          | Antihistamine   |
| Actions:                        | <ol> <li>Blocks histamine receptors</li> <li>Antiemetic effect</li> </ol>                             |
| Indications:                    | <ol> <li>Second Line for Anaphylaxis</li> <li>Dystonic reactions to antipsychotic drugs</li> </ol>    |
| Contraindications:              | <ol> <li>Hypersensitivity/allergy</li> <li>Weight &lt; 22 lbs (10 kg)</li> </ol>                      |
| Precautions:                    | May precipitate narrow angle glaucoma<br>BPH  |
| Side Effects:                   | Sedation, confusion<br>Anticholinergic effects such as urinary retention                              |
| Dosage:                         | <i>Adults:</i> Adults 25 to 50 mg slow PO/IV/IO/IM<br><i>Pediatric:</i> 1 mg/kg PO/IM/IV/IO NMT 50 mg |
| Supply:                         | Prefilled carpuject contains 50 mg (1 ml)<br>25 mg capsules   |
| Comments:                       | Reduce dose in elderly  |

# DOPAMINE (Intropin)

| Dopamine HCL (Int  | ropin) [EMT-P  |
|--------------------|--|
| Class:             | Sympathomimetic  |
| Actions:           | <ol> <li>Increases cardiac contractility</li> <li>Causes peripheral vasoconstriction</li> </ol>  |
|                    | 3. Increases chronotropic and inotropic effects  |
| Indications:       | Non-hypovolemic shock  |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Hypovolemic shock (volume replacement MUST be<br/>accomplished prior to using Dopamine)</li> </ol>  |
| Precautions        | Not compatible with Sodium Bicarbonate or other alkaline solution  |
| Side Effects:      | Tachycardia, hypertension, arrhythmias, chest pain   |
| Dosage:            | Adults: 5-20 mcg/kg/minIV/IO. Titrate to systolic BP ≥ 100.<br>Mix 400 mg in 250 ml D5W (1600 mcg/ml]).<br>Pediatric: Start at 2 – 5 mcg/kg/min IV/IO. Titrate for effect.<br>NMT 30 mcg/kg/min<br>Mix 100mg in 250ml D5W (400 mcg/ml)<br>Shake to mix |
| Supply:            | Vial contains 200 mg (5 ml)<br>Premixed – 1600mcg/250ml  |
| Comments:          | <ol> <li>Very Low Dose (0.5 - 2 mcg/kg/min): dopaminergic</li> <li>Low Dose (2 - 10 mcg/kg/min): β effects predominate</li> <li>High Dose (&gt; 10 mcg/kg/min):α effects predominate</li> </ol>  |

| mcg/kg/min   | Patient weight in kg |   |    |     |    |    |    |    |    |    |    |     |
|--|----------------------|---|----|-----|----|----|----|----|----|----|----|-----|
|  | 2.5                  | 5 | 10 | 20  | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
| 2 mcg  |                      |   |    | 1.5 | 2  | 3  | 4  | 5  | 5  | 6  | 7  | 8   |
| 5 mcg  |                      | 1 | 2  | 4   | 6  | 8  | 9  | 11 | 13 | 15 | 17 | 19  |
| 10 mcg   | 1                    | 2 | 4  | 8   | 11 | 15 | 19 | 23 | 26 | 30 | 34 | 38  |
| 15 mcg   | 1.4                  | 3 | 6  | 11  | 17 | 23 | 28 | 34 | 39 | 45 | 51 | 56  |
| 20 mcg   | 2                    | 4 | 8  | 15  | 23 | 30 | 38 | 45 | 53 | 60 | 68 | 75  |
| Microdrops per minute (or ml/hr)   |                      |   |    |     |    |    |    |    |    |    |    |     |
| Mix 400 mg in 250 ml D5W (1600 mcg/ml) or Mix 800 mg in 500 ml D5W (1600 mcg/ml) & run at: |                      |   |    |     |    |    |    |    |    |    |    |     |

# DROPERIDOL (Inapsine)

| Droperidol (Inapsin            | e) [EMT-P]  |
|--------------------------------|---|
| Class:                         | Neuroleptic   |
| Actions:                       | <ol> <li>Dopamine D2 receptor antagonist.</li> <li>Produces mild alpha-adrenergic blockade, peripheral vascular dilation, reduction of the pressor effect of epinephrine</li> <li>Produces marked tranquilization and sedation, allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness.</li> <li>Anti-emetic effect.</li> </ol>               |
| Indications:                   | <ol> <li>Sedation of combative patients to facilitate restraint.</li> <li>Nausea and vomiting not responsive to ondansetron</li> </ol>  |
| Contraindications:             | <ol> <li>Systolic BP &lt; 100</li> <li>Known QT prolongation (QTc &gt; 450 msec in females or &gt; 400 in males)</li> <li>CNS depression or coma</li> <li>Pregnancy</li> <li>Known allergy to droperidol</li> </ol>   |
| Precautions:                   | <ol> <li>Hypotension may occur; IV fluids and other measures to<br/>manage hypotension should be readily available.</li> <li>Use caution when administering droperidol to patients who<br/>have taken other CNS depressant drugs (barbiturates,<br/>tranquilizers, alcohol).</li> <li>Droperidol may induce Torsades de Pointes. Monitor the<br/>patient's ECG Q-T interval when possible following use.</li> </ol> |
| Side Effects:                  | <ol> <li>The most common side effects are hypotension and<br/>tachycardia which usually respond to a fluid bolus.</li> <li>Dysphoric (restlessness) and dystonic reactions have been<br/>reported following administration. These symptoms can be<br/>treated with the administration of Diphenhydramine.</li> </ol>  |
| Dosage: Patient restraint      | Adults: 2.5 mg IV or 5 mg IM. May repeat once in 10 minutes.<br>Pediatric: $\geq$ 14 yo, same as adult. For < 14 yo, OLMC consult   |
| Dosage: Nausea<br>and vomiting | Adults: 0.625 mg IV/IO. (0.625 mg = 0.25 ml based on a 5 mg/<br>2 ml package)<br>Pediatric: ≥ 14 yo, same as adult. For < 14 yo, OLMC consult   |
| Supply:                        | 5 mg / 2 ml vial  |
| Comments:                      | Onset of action is from 3-10 minutes following administration<br>and peak effect may not be apparent for up to 30 minutes.<br>Duration is generally 2-4 hours.  |

# DUONEB (Albuterol/Atrovent mix)

| Duoneb (Albuterol/ | Atrovent mix)   | [EMT/AEMT/EMT-I/RN/EMT-P]          |
|--------------------|---|------------------------------------|
| Class:             | Bronchodilator  |                                    |
| Actions:           | Smooth muscle relaxant.<br>Opens up narrowed breath   | ing passages                       |
| Indications:       | <ol> <li>Asthma</li> <li>Emphysema</li> <li>COPD</li> <li>Anaphylactic respiratory</li> </ol>   | y distress                         |
| Contraindications: | Albuterol or atrovent allergy   | у                                  |
| Precautions:       | Chest pain.<br>Pulse > 140 /min. (adults) o<br>Systolic B/P > 180<br>Narrow angle glaucoma  | or > 180/min. (children)           |
| Side Effects:      | Chest discomfort, angina.<br>Fast or irregular heartbeat  |                                    |
| Dosage:            | Adults & Pediatric: 3 ml via  | l in nebulizer.                    |
| Supply:            | 3 ml vial (Fish) containing   | 2.5 mg Albuterol/0.5 mg Atrovent   |
| Comments:          | <ol> <li>First line in adults.</li> <li>2nd line in children. (1s</li> <li>All subsequent neb trea<br/>directed otherwise by O</li> </ol> | atments are to be Albuterol unless |

#### ECALLANTIDE (Kalbitor)

| ECALLANTIDE (Kal                    | lbitor) [EMT-P  |
|-------------------------------------|---|
| Special<br>Administration<br>Order: | For patients with known diagnosis of Hereditary Angioedema<br>(HAE) who has signs or symptoms of laryngeal edema.<br>Patient carries 2 - 30 mg doses of drug (10mg/1ml vials)   |
| Class:                              | Kallikrein Blocker  |
| Actions:                            | Blocks the activity of a protein in the body called plasma<br>kallikrein, preventing the release of the chemical that causes<br>veins to leak fluid. This allows the pain and swelling associated<br>with HAE attack to improve.  |
| Indications:                        | HAE patient with signs & symptoms of laryngeal edema  |
| Contraindications:                  | Allergy to ecallantide  |
| Precautions:                        | Symptoms of a serious allergic reaction can be similar to the symptoms of hereditary angioedema.  |
| Side Effects:                       | <ol> <li>Anaphylaxis/serious allergic reaction</li> <li>Headache, nausea, diarrhea, fever, stuffy nose</li> <li>Injection site reactions, such as redness, rash, swelling, itching, or bruising</li> </ol>  |
| Dosage:                             | <ol> <li>Administered subcutaneously in three 10 mg (1 mL)<br/>injections. Injections should be minimum of 2" apart, in non-<br/>effected area - eg. thigh, arm, abdomen</li> <li>If an attack persists, an additional dose of 30 mg may be<br/>administered in 2 hours, NTE 20 mg within a 24-hour period</li> </ol>   |
| Supply:                             | 10mg/1ml vials  |
| Comments:                           | Laryngeal edema is the most worrisome feature of HAE,<br>because swelling can close the airway and cause death by<br>asphyxiation.<br>After administration patient must be transported to ED and<br>monitored for signs of a serious allergic reaction which may<br>include - wheezing, shortness of breath, cough, chest tightness<br>trouble breathing, dizziness, fainting, palpitations, swelling of<br>the throat or tongue, throat tightness, hoarse voice, trouble<br>swallowing, runny nose, nasal congestion or sneezing,<br>reddening of the face, itching, hives, or feeling warm. |

# EPINEPHRINE 1:1,000

| Epinephrine 1:1,000                                  | (Adrenalin)   | [*EMR/EMT/**AEMT/EMT-I/RN/EMT-P]  |  |  |  |  |  |
|--|---|---|--|--|--|--|--|
| Class:   | Sympathomimetic   |   |  |  |  |  |  |
| Actions:   | $\alpha$ - Vasoconstriction: improves coronary blood flow and supports BP in anaphylactic shock $\beta 1$ – Inotropic and chronotropic effects. |   |  |  |  |  |  |
| Indications:   | <ol> <li>ACLS: (VF, pulseles</li> <li>Anaphylaxis</li> <li>Stridor &amp; lower airway</li> </ol>  | s VT, Asystole, PEA)<br>ay wheezing not broken by albuterol   |  |  |  |  |  |
| Contraindications:                                   | Pediatric cardiac arrest  | (see Epinephrine 1:10,000)  |  |  |  |  |  |
| Precautions:   | 1. Chest pain   | ng unless symptoms are severe:<br>dults) or > 180/min. (children)   |  |  |  |  |  |
| Side Effects:  | Tachycardia, hypertension, arrhythmias, tremor, anxiety, headache, chest pain   |   |  |  |  |  |  |
| Dosage:<br>Anaphylaxis                               | heart disease.  | IM<br>IM  |  |  |  |  |  |
| Dosage:<br>Respiratory<br>Distress<br>**AEMT & above | severe respirate<br>Atrovent<br>May repeat this dose of<br>Use with caution if patie  | in nebulizer for stridor, wheezing or<br>bry distress not broken with Albuterol ±<br>nce after 10 min PRN<br>ent is 50 years or older or has history of<br>Consider OLMC consult before |  |  |  |  |  |
| Dosage:<br>ACLS<br>**AEMT & above                    | Adult & Pediatric: See E<br>Adult ETT: 2 mg ETT<br>Pediatric ETT only: 0.1  | Epinephrine 1:10,000 for IV/IO dosing<br>mg/kg ETT (0.1 ml/kg)<br>rine 1:10,000 for IV/IO/ET dosing   |  |  |  |  |  |
| Supply:  | 1 mg/ml, 30 ml or 1 ml  | vial  |  |  |  |  |  |
| Comments:  | IM route now recomme absorption in shock sta  | nded instead of SQ due to improved  |  |  |  |  |  |

# EPINEPHRINE 1:10,000

| Epinephrine 1:10  | 0,000 (Adr               | enalin)   |                                      |          |         |          | [EN   | /IT-I/RN                  | I/EMT-F |
|---|--------------------------|---|--------------------------------------|----------|---------|----------|-------|---------------------------|---------|
| Class:  | Symp                     | athomir   | netic                                |          |         |          |       |                           |         |
| Actions:  | suppo                    | $\alpha$ - Vasoconstriction: improves coronary blood flow and supports BP in anaphylactic shock $\beta 1$ – Inotropic and chronotropic effects.   |                                      |          |         |          |       |                           |         |
| Indications:  | 2. <mark>(E</mark><br>a. | <ol> <li>ACLS: (VF, pulseless VT, Asystole, PEA)</li> <li>(EMT-P Only)         <ul> <li>Pediatric Bradycardia unresponsive to ventilation</li> <li>Anaphylaxis not responding to IM treatment</li> </ul> </li> </ol>  |                                      |          |         |          |       |                           | 1       |
| Contraindicatior  | <b>is:</b> No ab         | solute i  | ndicatio                             | ons in A | CLS     |          |       |                           |         |
| Precautions:  | 1. Cł<br>2. Pu           | nest pai<br>Ilse > 1  | the follo<br>n<br>40/min.<br>P > 180 | (adults  |         |          |       |                           |         |
| Side Effects:   | -                        |   | hyperte<br>lest pai                  |          | arrhyth | mias, tr | emor, | anxiety                   | ,       |
| Dosage:<br>Anaphylaxis  | <i>Child/</i><br>Use v   | Adults: 0.1-0.3 mg (1-3 ml) IV/IO<br>Child/Infant: 0.01 mg/kg (0.1 ml/kg) IV/IO NMT 0.5 mg<br>Use with caution if patient is 50 years or older or has history of<br>heart disease. Consider OLMC consult before administration.   |                                      |          |         |          |       |                           |         |
| Dosage:<br>ACLS   | Adult:<br>Pedia          | <ul> <li>Adult: 1 mg (10 ml) IV/IO. Repeat every 3-5 minutes until pulse returns.</li> <li>Pediatric: 0.01-0.03 mg/kg (0.1-0.3 ml/kg) IV/IO. Repeat every 3-5 minutes until pulse returns or bradycardia resolves Neonatal: 0.01 mg/kg (0.1 ml/kg) IV/IO with 1 ml flush NS 0.05 mg/kg ETT (0.5 ml/kg) (+3 PPV breaths,no flush) Repeat every 3-5 minutes until HR &gt; 60 BPM</li> </ul> |                                      |          |         |          |       | t every<br>esolves.<br>IS |         |
| Supply:   | Preloa                   | ad 1 mg   | j /10 ml                             | (1 ml =  | = 0.1mg | )        |       |                           |         |
| <ul> <li>Epinephrine infu<br/>Mix 200 mcg in a<br/>Drip for 0.1 mcg.</li> </ul> | 50 mL NS (4              | l mcg/m   |                                      | er minu  | te      |          |       |                           |         |
| Pt wt (lbs)   | 4 66                     | 88  | 110                                  | 132      | 154     | 176      | 198   | 220                       | 242     |
| Pt wt (kg) 2  | 0 30                     | 40  | 50                                   | 60       | 70      | 80       | 90    | 100                       | 110     |
| mcg/min 2   | 3                        | 4   | 5                                    | 6        | 7       | 8        | 9     | 10                        | 11      |
|   | 0 45                     | 60  | 75                                   | 90       | 105     | 120      | 135   | 150                       | 165     |

#### ETOMIDATE (Amidate)

| Etomidate (Amidate | e) [EMT-P]  |
|--------------------|---|
| Class:             | Sedative/hypnotic Induction Agent   |
| Actions:           | Non-barbiturate hypnotic; lacks analgesic activity  |
| Indications:       | Induction for RSI   |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Sepsis/septic shock</li> </ol>   |
| Pregnancy:         | Category C - not recommended  |
| Precautions:       | <ol> <li>Excessively rapid injection may be followed by a fall in blood<br/>pressure.</li> <li>IV incompatibility with vecuronium</li> </ol>  |
| Side Effects:      | <ol> <li>Adrenal suppression</li> <li>Myoclonus</li> <li>Transient pain on injection</li> <li>Nausea/vomiting</li> </ol>  |
| Dosage:            | Adults: 0.3 mg/kg IV/IO<br>Pediatric: 0.3 mg/kg IV/IO<br>Administer undiluted over 10 - 20 seconds  |
| Supply:            | 2 mg/mL<br>Supplied in a pre-load syringe containing 40 mg in 20 mL   |
| Kinetics:          | <i>Onset:</i> within 60 seconds <i>Duration:</i> 3-5 minutes  |
| Comments:          | <ol> <li>First line induction agent for RSI.</li> <li>Advantages: Cerebroprotective and minimal myocardial/<br/>respiratory depression</li> <li>Disadvantages: Adrenal suppression/increased risk of death<br/>in septic patients.</li> </ol> |

#### FENTANYL (Sublimaze)

| Fentanyl (Sublimaz | e) [EMT-I/RN/EMT-P]  |
|--------------------|--|
| Class:             | Narcotic Analgesic   |
| Actions:           | <ul><li>Acts on the opiate receptors in the brain to cause:</li><li>1. Analgesia</li><li>2. CNS depression</li><li>3. Vasodilation</li></ul>   |
| Indications:       | <ol> <li>Hypersensitivity/allergy</li> <li>Treatment of acute pain if patient has allergy to Morphine</li> <li>1st line analgesic with the following:         <ul> <li>a. Traumatic injuries with severe pain</li></ul></li></ol>  |
| Contraindications: | <ol> <li>Respiratory depression</li> <li>Acute severe bronchial Asthma</li> <li>Within 2 weeks of MAO inhibitor use</li> </ol>   |
| Precautions:       | Use with Caution in patients with head injury at risk for ICH  |
| Side Effects:      | <ol> <li>Sedation</li> <li>Respiratory depression or arrest.</li> <li>Chest wall rigidity</li> <li>Bradycardia, QT-prolongation, arrhythmia</li> <li>Hypotension</li> <li>Nausea &amp; vomiting, constipation</li> <li>Raised ICP</li> </ol>   |
| Dosage:            | Adults: 25-100 mcg (0.5-1 mcg/kg) IV/IO/IM/IN<br>slowly over 1-2 min NMT 200 mcg<br>Pediatric: 1 mcg/kg IV/IO/IM slowly over 1-2 min NMT 4 mcg/kg<br>or 200 mcg. Repeat with ½ initial dose prn. Or, 2 mcg/<br>kg IN repeated with 1 mcg/kg every 5 minutes as<br>needed to a maximum of 8 mcg/kg. |
| Supply:            | Carpuject 100 mcg / 2 ml<br>100mcg/2ml Single Dose Vial (SDV)  |
| Kinetics:          | Onset:         2 – 3 min           Duration:         30 – 60 min   |
| Comments:          | <ol> <li>Approximately 80 times more potent than Morphine</li> <li>Rapid administration may cause muscle rigidity of<br/>respiratory muscles. Muscle rigidity may be treated with<br/>benzodiazepine, but may require treatment with paralytic.</li> </ol>   |

#### FUROSEMIDE (Lasix)

| Furosemide (Lasix) | [EMT-I/RN/EMT-P]  |
|--------------------|---|
| Class:             | Diuretic  |
| Actions:           | 1. Inhibits reabsorption of NaCl  |
|                    | 2. Promotes prompt diuresis   |
|                    | 3. Vasodilatation   |
| Indications:       | Pulmonary edema with signs and symptoms of volume overload                  |
|                    | (recent weight gain, peripheral edema, JVD, rales)                          |
| Contraindications: | 1. Hypersensitivity/allergy   |
|                    | 2. Systolic BP $< 100$  |
|                    | 3. Known severe hypokalemia   |
| Pregnancy:         | Category C - not recommended  |
| Precautions:       | 1. Should be not given prior to nitrates in patients with CHF               |
|                    | 2. Small risk of cross-reaction in patients with allergy to sulfa compounds |
|                    |   |
| Side Effects:      | 1. Hypotension  |
|                    | 2. Hypokalemia  |
| Dosage:            | Adults: 20 mg (2ml) IV/IO at 15-20 mg/min. 40 mg (4 ml) for                 |
| *                  | patients taking PO Lasix daily.   |
|                    | Pediatric: 1 mg/kg (0.1 ml/kg) IV/IO at 15-20 mg/min                        |
| Supply:            | Vial contains 40 mg (4 ml)  |
|                    | Ansyr LL Syringe – 40 mg / 4 ml   |
| Comments:          | *Note newer recommendations for reduced doses of lasix                      |

#### GLUCAGON

| Glucagon HCL       | [AEMT/EMT-I/RN/EMT-P]   |  |
|--------------------|---|--|
| Class:             | Hormone (Antihypoglycemic agent)  |  |
| Actions:           | <ol> <li>Causes breakdown of glycogen to glucose</li> <li>Elevates blood glucose level</li> </ol>   |  |
| Indications:       | <ul> <li>Unable to administer IV D50 in:</li> <li>1. Rapid glucose determination &lt; 70 mg/dl.</li> <li>2. Rapid glucose determination suspected stroke pt.&lt; 60 mg/dl</li> <li>3. Suspected hypoglycemia if: <ul> <li>a. GCS ≤ 12</li> <li>b. Seizure lasting ≥ 3 min.</li> </ul> </li> </ul> |  |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Pheochromocytoma</li> </ol>  |  |
| Precautions:       | Caution if history of pheochromocytoma or insulinoma  |  |
| Side Effects:      | Nausea, vomiting, hyperglycemia   |  |
| Dosage:            | Adults: 1 mg (1 ml) IM/IV/IO q 20 min PRN<br>Pediatric: 0.02 mg/kg IM/IV/IO NMT 1 mg (1 ml)<br>q 20 min PRN   |  |
| Supply:            | Vial containing 1 mg powder<br>Mix with vial containing 1 ml diluent for 1 mg/ml solution   |  |
| Comments:          | <ol> <li>May be useful in β-blocker or Ca-channel blocker overdose.<br/>Requires significant quantity to be effective.</li> <li>Call OLMC for dosing in overdose.</li> </ol>  |  |

#### HALOPERIDOL LACTATE (Haldol)

| Haloperidol Lactate            | (Haldol) [EMT-P  |  |  |  |
|--------------------------------|--|--|--|--|
| Class:<br>Actions:             | Neuroleptic  |  |  |  |
|                                | <ol> <li>Dopamine D2 receptor antagonist.</li> <li>Produces mild alpha-adrenergic blockade, peripheral vascular dilation, reduction of the pressor effect of epinephrine</li> </ol>  |  |  |  |
|                                | <ol> <li>Produces marked tranquilization and sedation, allays<br/>apprehension and provides a state of mental detachment<br/>and indifference while maintaining a state of reflex alertness.</li> </ol>  |  |  |  |
|                                | 4. Anti-emetic effect.   |  |  |  |
| Indications:                   | <ol> <li>Sedation of combative patients to facilitate restraint.</li> <li>Nausea and vomiting</li> </ol>   |  |  |  |
| Contraindications:             | <ol> <li>Known allergy to haloperidol</li> <li>CNS depression or coma</li> </ol>   |  |  |  |
| Precautions:                   | <ol> <li>Hypotension may occur; IV fluids and other measures to<br/>manage hypotension should be readily available.</li> <li>Use caution when administering haloperidol to patients who<br/>have taken other CNS depressant drugs (barbiturates,<br/>tranquilizers, alcohol).</li> <li>Haloperidol may induce Torsade de Pointes. Monitor the</li> </ol> |  |  |  |
|                                | patient's ECG Q-T interval following use.  |  |  |  |
| Side Effects:                  | <ol> <li>EPS: muscle stiffness, dystonia, parkinsonism, tardive<br/>dyskinesa</li> <li>NMS: Neuroleptic Malignant Syndrome - potentially fatal<br/>reaction to neuroleptic medications causing altered mental<br/>status, rigidity, hyperthermia, and dysautonomia</li> <li>Sedation, anticholinergic effects</li> </ol>                                 |  |  |  |
|                                |  |  |  |  |
| Dosage: Patient<br>restraint   | Adults: 5-10 mg IV, IO, IM. May repeat to a maximum of 20 mg<br>Pediatric: > 12 yo, same as adult. For < 12 yo, OLMC consult   |  |  |  |
| Dosage: Nausea<br>and vomiting | Adults: 1.25 mg IV/IM<br>Pediatric: Not authorized for < 12 yo   |  |  |  |
| Supply:                        | 5 mg / 1 ml vial   |  |  |  |
| Comments:                      |  |  |  |  |
| comments:                      |  |  |  |  |

#### HYDROXYCOBALAMIN (Cyanokit)

| Hydroxycobalamin   | [EN   | 1T-P]                  |
|--------------------|---|------------------------|
| Class:             | Cyanide antidote  |                        |
| Actions:           | A. Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to inhibition of cytochrome oxidase resulting in arrest of cellular respiration B. Hydroxocobalamin (Vitamin B12a) is an effective antidote the treatment of cyanide poisoning based on its ability to bir cyanide ions. Each hydroxocobalamin (vitamin B12), which is then excreted in the urine. | n.<br>e in<br>nd<br>ne |
| Indications:       | Coma, persistent hypotension or cardiorespiratory arrest in setting of suspected cyanide poisoning or smoke inhalation  | the                    |
| Contraindications: | None known  |                        |
| Precautions:       | Hydroxocobalamin has physical (particulate) and chemical<br>incompatibilities with many medications and it is best to<br>administer all other drugs or products (e.g., blood) through a<br>separate intravenous line.   | a                      |
| Side Effects:      | <ul> <li>A. Serious side effects include allergic reactions, temporary increases in blood pressure, nausea, headache and infusion site reactions.</li> <li>B. Common side effects are chromaturia (red-colored urine and erythema (skin redness) which occur in nearly all patier May cause skin photosensitivity</li> </ul>  | n<br>)                 |
| Dose:              | Adults: 5 grams (2 vials) IV, IO over 15 minutes<br>Pediatric: 70 mg/kg IV, IO over 15 minutes<br>May repeat 5 grams or 70 mg/kg over 15 minutes to 2 hours<br>NMT 10 grams after OLMC contact.   | s to                   |
| Supply:            | 2.5 gram vials. Each 2.5 gram vial of hydroxycobolamin sho<br>be reconstituted with 100 mL of Normosol. May store for up<br>6 hours at room temp.   |                        |
| Comments:          | <ul> <li>A. Hydroxocobalamin interferes with laboratory tests based light absorption including co-oximetric measurements of carboxyhemoglobin, methemoglobin and oxyhemoglobin.</li> <li>B. If patient has suspected cyanide poisoning, consider obtaining SpCO, if available, before administration of Cyano</li> </ul>  |                        |

#### IV SOLUTION (BSS)

| IV Solution (BSS)  | [AEMT/EMT-I/RN/EMT-P]  |
|--------------------|--|
| Class:             | Electrolyte/Fluid Replacement  |
| Actions:           | Provide water and electrolytes for replacement of acute extracellular fluid losses   |
| Indications:       | <ol> <li>Hypotension</li> <li>PEA</li> <li>Dehydration, moderate to severe, due to:         <ul> <li>a. Inadequate intake</li> <li>b. Acute loss from vomitting and/or diarrhea</li> </ul> </li> <li>Acute blood loss due to:         <ul> <li>a. Trauma</li> <li>b. GI Bleeding</li> </ul> </li> </ol>  |
| Contraindications: |  |
| Precautions:       | Caution in patients with:<br>1. Renal impairment<br>2. CHF/Pulmonary edema<br>3. Extremes of age.  |
| Side Effects:      | Fluid overload resulting in pulmonary edema  |
| Dosage:            | <ul> <li>Adults: 500 - 1000 mL bolus BSS IV/IO<br/>May repeat bolus PRN NMT 2 L</li> <li>Pediatric: 10 - 20 mL/kg bolus NS IV/IO<br/>May repeat bolus PRN NMT 40 mL/kg</li> <li>Neonatal: 10 mL/kg bolus NS IV/IO over 5 - 10 min only if<br/>signs of shock or history of acute blood loss and<br/>not responding to initial resuscitation (HR &lt; 60).<br/>May repeat bolus PRN NMT 20 mL/kg</li> </ul> |
| Supply:            | 100, 250, 500 and 1,000 ml bags of either Lactated Ringers or Normal Saline 0.9%   |
| Comments:          | NS is initial fluid of choice. May consider LR in trauma patients requiring more than 2 boluses of BSS.<br>Warmed fluids in trauma patients if available.<br>Chilled (4° C) fluids in ROSC to induce hypothermia<br>Reassess fluid status and lung sounds between boluses.<br>In elderly or patients with history of CHF or renal failure, use<br>caution and bolus in increments of 250 mL.               |

#### KETAMINE (Ketalar)

| Ketamine (Ketalar) | [EMT-F  |
|--------------------|---|
| Class:             | Sedative, Analgesic   |
| Actions:           | 1. Analgesia  |
|                    | 2. Amnesia  |
|                    | 3. Releases endogenous catecholamines   |
|                    | 4. Dilates bronchial smooth muscles   |
|                    | 5. Stimulates beta receptors in the lungs   |
| Indications:       | 1. Induction for RSI  |
|                    | 2. Chemical sedation for agitated patient   |
|                    | 3. 3rd line for severe pain control   |
| Contraindications: | 1. Hypersensitivity/allergy   |
|                    | 2. Acute globe injury   |
| Precautions:       | 1. Known or suspected schizophrenia   |
|                    | 2. Coronary artery disease  |
|                    | 3. Glaucoma   |
| Pregnancy:         | Category B  |
| Kinetics           | 1. Onset: IV 30 seconds, IM 3-4 minutes   |
|                    | 2. Duration: IV 5-10 min; IM 15 - 30 minutes  |
| Side Effects:      | 1   an/ngooncom   |
| Side Lifects.      | 1. Laryngospasm   |
|                    | <ol> <li>2. Hypersalivation</li> <li>3. Emesis</li> </ol>   |
|                    |   |
|                    | 4. Hypertension   |
|                    | 5. Emergence reaction   |
|                    | 6. Possible increase intracranial and intraocular pressure  |
| Dosage:            | 1. RSI - IV/IO: Adults & Pediatric: 2 mg/kg over 60 seconds,  |
|                    | IM: Adults & Pediatric: 4 mg/kg   |
|                    | *If patient is known to be <i>pregnant</i> reduce dose to   |
|                    | 1 mg/kg IV/IO or 2 mg/kg IM   |
|                    | <ol> <li>Chemical Restraint: Adults &amp; Pediatric: up to 5 mg/kg IM or<br/>titrate 1 - 2 mg/kg IV/IO</li> </ol>                           |
|                    | <ol> <li>Pain Control: Adults 25 mg IV/IO slow push or 50 mg IM<br/>Pediatric: Not approved for use for pain control in patients</li> </ol> |
|                    | < 15 yo   |
|                    | 0.3 mg/kg NMT 25 mg IV/IO over 60 seconds   |
|                    |   |

| Comments: | 1. Phencyclidine (PCP) derivative which causes dissociative                |
|-----------|--|
| oonnents. | •  |
|           | anesthesia at higher dose, and analgesia at lower doses                    |
|           | 2. Does not inhibit protective airway reflexes, spontaneous                |
|           | respirations or cardiopulmonary stability.                                 |
|           | 3. Monitor closely for laryngospasm. Treatment of                          |
|           | laryngospasm consists of removing the noxious stimulus                     |
|           | (eg, by suctioning blood or secretions) and employing                      |
|           | positive pressure bag-mask ventilation concurrent with a jaw               |
|           | thrust maneuver. If bag-mask ventilation is not successful, a              |
|           | 5  |
|           | small dose of succinylcholine (0.1 mg/kg IV) may be                        |
|           | administered   |
|           | <ol><li>Administer midazolam 2.5 - 5 mg IV/IO in adults to treat</li></ol> |
|           | severe emergence reaction  |
|           | 5. Good choice in Asthma/COPD due to bronchodilator effects                |
|           | 6. *Safety in pregnancy has not been established, but no                   |
|           |  |
|           | evidence of teratogenicity. May be used in pregnancy, but                  |
|           | use reduced dose   |

# KETOROLAC (Toradol)

| KETOROLAC (Torad   | lol)     | [EMTI/RN/P   |
|--------------------|----------|--|
| Class:             | 1.       | NSAID (Non-Steroidal Anti-inflammatory Drug)   |
|                    |          | Analgesic  |
|                    | 2.<br>3. | •  |
|                    | 3.       | Аппругенс  |
| Actions:           | 1.       | Inhibits cyclooxygenase resulting in decreased   |
|                    |          | prostaglandin synthesis  |
| Indications:       | Sh       | ort-term management of moderate to severe acute pain:  |
|                    |          | Acute flank/abdominal pain likely secondary to kidney stone  |
|                    | 2.       | Musculoskeletal pain without significant trauma or bleeding  |
| Controindiactiona  | 4        |  |
| Contraindications: |          | Aspirin or NSAID <b>allergy</b><br><b>Bleeding disorders</b> or patients with high risk of bleeding  |
|                    |          | such as major trauma or anticipated need for surgery   |
|                    | 3        | Head trauma or risk of <b>cerebrovascular bleeding</b>   |
|                    |          | History of peptic ulcer disease, <b>GI bleed</b> or perforation                                      |
|                    |          | History of <b>renal impairment</b> or is at risk of acute renal                                      |
|                    | э.       | failure due to volume depletion  |
|                    | 6        | 3rd trimester <b>Pregnancy</b>   |
|                    | 0.       | (can cause premature closure of ductus arteriosus)   |
|                    | 7.       |  |
|                    | 1.       | Nursing Mothers (excleted in breast milk)  |
| Precautions:       | 1.       | Coagulation therapy - do not give if taking anticoagulants   |
|                    | _        | such as warfarin, rivaroxaban, apixaban, Lovenox, etc  |
|                    | 2.       | Potential risk of cardiovascular damage - do not give if<br>history of CHF or suspected acute MI/CHF |
|                    | 0        |  |
|                    |          | Do not give if patient has taken oral NSAIDs in past 6 hours   |
|                    |          | History of hepatic impairment  |
|                    |          | Elderly - do not give if > 65 yo   |
|                    | 6.       | Children - do not give if < 2 yo   |
| Pregnancy:         | Ca       | ategory C  |
|                    |          |  |
| Kinetics           | 1.       | Onset: 1 - 10 minutes IV; 15 - 45 minutes IM   |
|                    | 2.       | Duration: 6 - 8 hours  |
| Side Effects:      | 4        | Ananhylavia branchasnasm anglasdama  |
|                    |          | Anaphylaxis, bronchospasm, angioedema  |
|                    |          | CNS - headache, dizziness, drowsiness, depression  |
|                    |          | CV- edema, hypertension, vasodilatation, hypotension   |
|                    | 4.       | Renal/Electrolytes - urinary rentention or failure,  |
|                    |          | hynonatremia hynerkalemia  |
|                    | F        | hyponatremia, hyperkalemia   |
|                    |          | GI - pain, dyspepsia, nausea/vomiting, diarrhea, constipation  |
|                    |          | •••  |

#### KETOROLAC (Toradol) (continued)

| Dosage:   | Adults (>50 kg & < 65 yo): 60 mg IM; 30 mg IV/IO<br>Adults (< 50 kg & < 65 yo): 30 mg IM; 15 mg IV/IO<br>Pediatric (> 2 yo): 0.5 mg/kg IV to a max of 15 mg;<br>1 mg/kg IM to a max of 30 mg<br>Not recommended for children under 2 years of age |  |  |  |  |
|-----------|---|--|--|--|--|
| Supply:   | Tubex 15mg/ml (1 ml); 30mg/ml (1 ml)<br>30mg/1ml SDV  |  |  |  |  |
| Comments: |   |  |  |  |  |

#### LIDOCAINE (Xylocaine)

| Lidocaine HCL (Xyl | ocaine) [EMT-I/RN/EMT-P   |
|--------------------|---|
| Class:             | Antiarrhythmic  |
| Actions:           | 1. Suppresses ventricular ectopy                                      |
|                    | 2. Elevates threshold of ventricular fibrillation                     |
|                    | 3. Decreases ventricular automaticity                                 |
| Indications:       | 1. Cardiac arrest from V-Fib/V-Tach                                   |
|                    | 2. Stable V-Tach  |
|                    | 3. Pain from IO in conscious patient                                  |
| Contraindications: | 1. Hypersensitivity/allergy   |
| contrainuications. | 2. Slow V-Tach (heart rate < 100/min., QRS $\ge$ 0.12 sec)            |
|                    | 3. Bradycardia (heart rate < $60$ /min. adult; < $80$ /min. children) |
|                    | 4. Torsades de pointes  |
| Precautions:       | 1. Reduce maintenance dose in liver or LV dysfunction                 |
| Flecaulions.       | 2. Discontinue immediately if signs of toxicity develop               |
|                    |   |
| Side Effects:      | 1. Decreased LOC, dizziness, confusion, numbness, seizures            |
|                    | 2. Arrhythmia, hypotension, cardiac arrest                            |
|                    | 3. Malignant hyperthermia   |
| Dosage:            | Adults: 1.5 mg/kg rapid IV/IO PRN q 5 min NMT 3 mg/kg.                |
| Cardiac Arrest     | 3 mg/kg ET (one dose only).   |
|                    | <i>Pediatric:</i> 1 mg/kg rapid IV/IO PRN q 5 min NMT 100 mg.         |
|                    | 3 mg/kg ET (one dose only).   |
| Dosage:            | Adults: 1.5 mg/kg IV/IO at 50 mg/min. or 3 mg/kg ET.                  |
| Wide QRS           | Repeat IV doses: 0.75 mg/kg at 50 mg/ min q 5 min                     |
| Tachycardia        | NMT 2 doses (3 mg/kg total).  |
|                    | Pediatric: 1.0 mg/kg IV/IO over 1 minute or 2 mg/kg ET.               |
|                    | Repeat IV doses: 1.0 mg/kg over 1 minute every 5 min                  |
|                    | NMT 2 doses (3 mg/kg total).  |
|                    | Avoid additional doses in CHF, shock, liver failure, and age > 70     |
| Dosage:            | *Adults & Pediatric: 0.5 mg/kg IO NMT 50 mg.                          |
| Conscious IO       | (See Hixson Lidocaine Chart on following page)                        |
|                    | Onset 30 – 60 seconds   |
| Supply:            | Prefilled syringe: 100 mg (5 ml) 2% solution                          |
| ,                  | Pre-mixed: 2 gm in 250 ml D5W bag                                     |
| Commonto:          | *A ENT con edminister on enerthetic for conscious 10                  |
| Comments:          | *A-EMT can administer as anesthetic for conscious IO                  |

# « Back Hixson Lidocaine Chart

| AGE  | WEIGHT<br>(KG) | VOLUME OF 2% (ML)<br>1ML OF 2% = 20 MG/ML |                  | VOLUME OF 1% (ML)<br>1ML OF 1% = 10 MG/ML |              |
|--|----------------|---|------------------|---|--------------|
|  |                | Initial                                   | Subsequent       | Initial                                   | Subsequent   |
| Neonate  | 3              | 0.07                                      | 0.03             | 0.15                                      | 0.07         |
| Neonate  | 4              | 0.1                                       | 0.05             | 0.2                                       | 0.1          |
| 7 weeks  | 5              | 0.12                                      | 0.06             | 0.25                                      | 0.12         |
| 3 months   | 6              | 0.15                                      | 0.07             | 0.3                                       | 0.15         |
| 5 months   | 7              | 0.17                                      | 0.08             | 0.35                                      | 0.17         |
| 7 months   | 8              | 0.2                                       | 0.1              | 0.4                                       | 0.2          |
| 1 year   | 9              | 0.22                                      | 0.11             | 0.45                                      | 0.22         |
| 15 months  | 10             | 0.25                                      | 0.12             | 0.5                                       | 0.25         |
| 2 years  | 12             | 0.3                                       | 0.15             | 0.6                                       | 0.3          |
| 3 years  | 14             | 0.35                                      | 0.17             | 0.7                                       | 0.35         |
| 4 years  | 16             | 0.4                                       | 0.2              | 0.8                                       | 0.4          |
| 5 years  | 18             | 0.45                                      | 0.22             | 0.9                                       | 0.45         |
| 6 years  | 20             | 0.5                                       | 0.25             | 1   | 0.5          |
| 7 years  | 23             | 0.57                                      | 0.28             | 1.1                                       | 0.57         |
| 8 years  | 26             | 0.65                                      | 0.32             | 1.3                                       | 0.65         |
| 9 years  | 29             | 0.72                                      | 0.36             | 1.4                                       | 0.72         |
| 10 years   | 32             | 0.8                                       | 0.4              | 1.6                                       | 0.8          |
| 11 years   | 35             | 0.87                                      | 0.43             | 1.7                                       | 0.87         |
| 12 years   | 39             | 0.97                                      | 0.48             | 1.9                                       | 0.97         |
| 13 years   | 44             | 1.1                                       | 0.55             | 2.2                                       | 1.1          |
| 14 years   | 50             | 1.2                                       | 0.62             | 2.5                                       | 1.2          |
| 15 years   | 54             | 1.3                                       | 0.67             | 2.6                                       | 1.3          |
| 16 years   | 58             | 1.4                                       | 0.72             | 2.8                                       | 1.4          |
|  | 60             | 1.5                                       | 0.75             | 3   | 1.5          |
| Adult  | 70             | 1.7                                       | 0.87             | 3.4                                       | 1.7          |
|  | 80+            | 2   | 1                | 4   | 2            |
| The lower vo   | lumes of 2% li | idocaine (<1 ml)                          | may be difficult | Volume                                    | Syringe Size |
| to accurately  | / measure and  | use of, or dillutio                       | on ťo, 1%        | 0 - 1 ml                                  | 1 ml         |
| lidocaine should be considered under these cirumstances.<br>Use the appropriate syringe site for the volume to |                |   | 1 - 2.5 ml       | 2.5 ml                                    |              |

Copyright 2012 richard Hixson, Md. All rights reserved. While all care has been taken to ensure that doses and recommendations are correct, responsibility for any decision made or action taken in reliance on such information rests with the prescriber.

### MAGNESIUM SULFATE

| Magnesium Sulfate   | 50% [EMT-P]  |  |
|---|--|--|
| Class:  | Anticonvulsant   |  |
| Actions:  | <ol> <li>CNS depressant</li> <li>Anticonvulsant</li> <li>Smooth muscle relaxant (vasodilation, bronchodilation)</li> </ol>   |  |
| Indications:  | <ol> <li>Refractory V-Fib and Pulseless V-Tach</li> <li>Cardiac arrest with suspected hypomagensemia</li> <li>Torsades de Pointes</li> <li>Eclampsia</li> <li>Asthma not responding to other treatments</li> </ol>   |  |
| Contraindications:  | <ol> <li>Hypersensitivity/allergy</li> <li>Complete heart block</li> </ol>   |  |
| Precautions:  | Monitor reflexes in Eclampsia<br>Monitor closely for hypotension in asthmatics   |  |
| Side Effects:   | Hypotension, bradycardia, complete heart block<br>Respiratory paralysis,<br>Depressed reflexes, confusion, flushing, sweating,   |  |
| Dosage: Asthma  | <i>Adults:</i> 2 gm (20 ml of 10% solution) IV/IO over 10-20 minutes<br><i>Pediatric:</i> 25 - 50 mg/kg IV/IO over 10 - 20 min NMT 2 gm  |  |
| Dosage: V-Fib/<br>Pulseless V-tach/<br>Torsades de<br>Pointes | Adults: 2 gm (20 ml of 10% Solution) IV/IO over 1 minute.<br>May repeat in 5 min PRN NMT 4 gm<br>Pediatric: 25 mg/kg IV/IO drip over 10 – 20 mins. NMT 2 gm  |  |
| Dosage:<br>Eclampsia  | 4 gm (40 ml of 10% solution) IV/IO over 4 minutes  |  |
| Supply:   | Vial contains 10 gm/ 20 ml = 1 gm/2 ml (a 50% solution)  |  |
| Comments:   | <ol> <li>10% solution: Add 8 ml of Normal Saline to each 1 gm<br/>(2 ml) of Magnesium Sulfate</li> <li>Magnesium drip: Add dose of Magnesium Sulfate to<br/>50 ml NS. Run through macro drip @ approx 38gtt/min<br/>for 20 min delivery.</li> <li>In VF/VT, when the patient appears malnourished,<br/>alcoholic or rhythm suggests Torsades de Pointes,<br/>give magnesium sulfate before other anti-dysrhythmics.</li> </ol> |  |

## MIDAZOLAM (Versed)

| Midazolam HCL (Ve  | rsed) [EMT-P]  |
|--|--|
| Class:   | Sedative, hypnotic (Benzodiazepine)  |
| Actions:   | Sedation by direct action on CNS   |
| Indications:   | <ol> <li>Seizures</li> <li>Sedation</li> <li>Chemical restraint</li> <li>Shivering during induced hypothermia</li> </ol>   |
| Contraindications:   | <ol> <li>Hypersensitivity/allergy</li> <li>Hypotension</li> <li>Shock</li> <li>Coma</li> </ol>   |
| Precautions:   | Most likely to produce respiratory depression in patients who<br>have taken other depressant drugs, especially opioids, alcohol<br>and barbiturates, or when given rapidly.  |
| Side Effects:  | <ol> <li>Respiratory depression, apnea</li> <li>Hypotension</li> <li>Drowsiness, dizziness, fatigue, amnesia, and ataxia</li> </ol>  |
| Dosage:<br>RSI   | Adults: 0.3 mg/kg IM/IV/IO NMT 20 mg<br>Consider lower dose (0.2 mg/kg) in patients over 60 yo<br>Pediatric: 0.2 mg/kg IM/IV/IO<br>< 6 y.o. NMT 3 mg<br>> 6 y.o. NMT 5 mg<br>May repeat every 15 min PRN post-intubation to maintain<br>sedation |
| Dosage:<br>Seizures<br>Chemical Restraint<br>Sedation<br>Cardioversion | Adults: 2 – 5 mg IV/IO/IM/IN<br>May repeat in 5 min NMT 10 mg total<br>Pediatric: 0.05 – 0.1 mg/kg IV/IO NMT 2.5 mg;<br>0.2 mg/kg IM/IN NMT 5 mg<br>May repeat in 5 min NMT 5 mg total   |
| Supply:  | 10mg / 2ml<br>2mg / 2ml  |
| Comments:  | Advanced airway management equipment must be readily<br>available.<br>Be prepared for respiratory depression   |

#### MORPHINE SULFATE

| Morphine Sulfate   | [EMT-I/RN/EMT-P]  |
|--------------------|---|
| Class:             | Narcotic Analgesic  |
| Actions:           | Acts on the opiate receptors in the brain to cause:<br>1. Analgesia<br>2. CNS depression<br>3. Vasodilation   |
| Indications:       | <ol> <li>Acute pain from isolated extremity trauma, back spasms,<br/>burns, kidney stones, non-traumatic abdominal pain</li> <li>Chronic pain from cancer</li> </ol>  |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Multiple trauma, especially head trauma</li> <li>Decreased LOC from any cause</li> <li>Systolic BP &lt; 110 (children: systolic BP &lt; 80)</li> <li>RR &lt; 14 breaths per minute, O2 saturation less than 90%, or significant respiratory depression.</li> </ol> |
| Precautions:       | For pediatric patients, vital signs should be maintained within the normal age-appropriate range.   |
| Side Effects:      | <ol> <li>Sedation</li> <li>Respiratory depression or arrest.</li> <li>Hypotension</li> <li>Nausea &amp; vomiting, constipation</li> </ol>   |
| Dosage:            | Adults: 2 - 5 mg IV/IO; 5 mg – 10 mg IM.<br>May repeat q 5 min PRN NMT 10 mg<br>(NMT 20 mg in burn patients)<br>Pediatric < 20 kg: 0.1 mg/kg IV/IO/IM<br>May repeat q 5 min PRN NMT 4 mg<br>For children > 20 kg, follow adult dosing   |
| Supply:            | Vial contains 10 mg (1 ml)<br>Carpuject 10 mg/1 ml  |
| Comments:          | With the exception of chronic pain from a terminal illness such<br>as cancer, opiates should not be administered in the field to<br>patients with chronic pain syndromes.   |

## NALOXONE (Narcan)

| Naloxone (Narcan)  | [*EMR/EMT/AEMT/EMT-I/RN/EMT-P]  |  |
|--------------------|---|--|
| Class:             | Narcotic Antagonist   |  |
| Actions:           | Reverses effects of narcotics by competing for opiate receptors.  |  |
| Indications:       | <ol> <li>Altered mental status with:         <ul> <li>a. Respiratory depression</li> <li>b. Systolic BP &lt; 90</li> <li>c. Suspected narcotic overdose.</li> </ul> </li> <li>Cardiopulmonary arrest when narcotic overdose is suspected</li> </ol>   |  |
| Contraindications: | 1. Hypersensitivity/allergy   |  |
| Precautions:       | May precipitate withdrawal seizures in neonates of narcotic addicted mothers.   |  |
| Kinetics           | <ol> <li>Onset: 1 -2 min IV/IO; 2-5 min IM</li> <li>Duration: 1 - 4 hours</li> </ol>  |  |
| Side Effects:      | May precipitate withdrawal. Awakened or awakening patient may become anxious or combative and may develop nausea/ vomiting.   |  |
| Dosage:            | Adults: 0.4 - 4 mg IV/IO/IM/SL/IN NMT 8 mg<br>Pediatric (< 20 kg): 0.1mg/kg IV/IO/IM/SL/IN NMT 2 mg;<br>For children > 20 kg, follow adult dosing   |  |
| Supply:            | Carpuject contains 2 mg<br>Prefilled Syringe – 2 mg<br>Prefilled IN devices - 4 mg  |  |
| Comments:          | In most instances, a total dose of 2 mg will be sufficient to<br>reverse opioid intoxication. In cases of methadone or designer<br>drugs, larger doses of naloxone may be necessary, up to a<br>MAX of 8 mg of naloxone. If no reaction, consider other causes.<br>Halt the IV injection if agitation occurs.<br>Reversal of coma, hypotension and respiratory depression is<br>only temporary.<br><b>IN is preferred route to avoid the risk of accidental<br/>needlestick</b><br>*EMRs may administer naloxone via IN or auto-injector only |  |

#### NITROGLYCERIN

| Nitroglycerin (Nitro             |   |
|----------------------------------|---|
| paste)                           | *EMT can assist patient with own NTG only   |
| Class:                           | Coronary vasodilator  |
| Actions:                         | <ol> <li>Dilatation of coronary arteries</li> <li>Reduces peripheral vascular resistance</li> <li>Reduces cardiac work</li> </ol>   |
| Indications:                     | <ol> <li>Angina - chest pain presumed due to coronary disease</li> <li>Pulmonary Edema</li> <li>Hypertensive emergency</li> </ol>   |
| Contraindications:               | <ol> <li>Hypersensitivity/allergy</li> <li>Systolic BP &lt; 100</li> <li>NTG is contraindicated in patients who have recently taken<br/>Viagra® (sildenafil citrate) or Levitra® (vardenafil HCI)<br/>within 24 hours OR taken Cialis® (tadalafil) within 48 hours.</li> </ol>  |
| Precautions:                     | Should be avoided in acute CVA<br>Use cautiously in suspected R sided MI or bradycardic patients  |
| Side Effects:                    | Hypotension, tachycardia, syncope, headache.  |
| Dosage: Angina/<br>CHF/HTN       | Adults: 0.4 mg SL q 5 minutes PRN chest pain NTE 3 doses.<br>Hold for systolic BP < 100.<br>Nitropaste - 1" to ACW if SBP remains >160 mm Hg<br>and/or the DBP is >100 mm Hg  |
| Dosage: Autonomic<br>Dysreflexia | <i>Adults:</i> Nitropaste - 1" to ACW if SBP remains >150 mm Hg<br>after conservative measures. (Can give SL ntg if<br>nitropaste unavailable)  |
| Supply:                          | Tablet: 0.4 mg<br>Pump Spray: each squirt = 0.4 mg<br>Packets containing 2 % ointment (1 inch/packet)   |
| Comments:                        | <ol> <li>An IV should be attempted prior to nitroglycerin<br/>administration. If unsuccessful with IV, give NTG SL, then<br/>reattempt IV.</li> <li>In inferior STEMI with suspected RV infarct, consider IV fluid<br/>bolus to increase preload before NTG administration</li> <li>Wear gloves when applying ointment.</li> <li>Because nitroglycerin causes generalized smooth muscle<br/>relaxation, it may also be effective in relieving chest pain<br/>caused by esophageal spasm.</li> </ol> |

#### NOREPINEPHRINE (Levophed)

| Norpinephrine (Lev | ophed) [EMT-F   |
|--------------------|---|
| Class:             | Sympathomimetic   |
| Actions:           | <ol> <li>Alpha-1 &gt;&gt; Beta-1 &gt; Beta-2 adrenergic agonist activity</li> <li>Has chronotropic and inotropic effects - increases cardiac output (CO)</li> <li>Causes peripheral vasoconstriction - increases systemic vascular resistance (SVR)</li> </ol>  |
| Indications:       | 1st line pressor in septic, cardiogenic and hypovolemic shock   |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Hypovolemic shock (volume replacement MUST be<br/>accomplished prior to using pressors)</li> </ol>   |
| Precautions        | Can cause tissue necrosis if extravasates   |
| Side Effects:      | Tachycardia, hypertension, arrhythmias, chest pain  |
| Dosage:            | Adults: Start at 4 mcg/min IV/IO.<br>Titrate to SBP ≥ 90 mmHg or MAP ≥ 65<br>(except in hemorrhagic shock: target SBP 70 - 90),<br>NMT 12 mcg/min<br>Mix 200 mcg (0.2 mL) in 50 ml D5W or NS (4 mcg/ml)<br>Pediatric: Start at 0.1 mcg/kg/min IV/IO. Titrate upward by 0.1<br>mcg/kg/min increments to age appropriate SBP. NMT<br>0.2 mcg/kg/min<br>Shake to mix |
| Supply:            | 4 mg / 4 ml Vial  |
| Comments:          |   |

## OLANZAPINE (Zyprexa)

| Olanzapine         | [EMT-P]  |
|--------------------|--|
| Class:             | Antipsychotic  |
| Actions:           | <ol> <li>Dopamine and serotonin (5-HT) antagonist, along with<br/>anticholinergic, antihistaminic, and anti-alpha adrenergic<br/>effects.</li> <li>Anxiolytic properties.</li> </ol>   |
|                    |  |
| Indications:       | <ol> <li>For the cooperative adult patient between 18-65 years. with<br/>a primarily behavioral health presentation and a history of<br/>psychiatric disorder. These patients will commonly be<br/>hearing voices or having paranoid thoughts after not taking<br/>their usual psychiatric medications.<br/>(RASS +1, see <b>Patient Restraint Protocol</b>)</li> <li>To avoid the need for physical restraint.</li> </ol> |
|                    |  |
| Contraindications: | <ol> <li>Patients less than 18 or greater than 65 years of age.</li> <li>FDA Black Box warnings for increased mortality in elderly<br/>patients with dementia</li> <li>Known hypersensitivity.</li> </ol>  |
|                    |  |
| Precautions:       | <ol> <li>May prolong QT but unlikely in single dose. Obtain EKG<br/>before administration if known history or suspicion for<br/>prolonged QT or cardiovascular disease.</li> </ol>   |
| Side Effects:      | 1. Low incidence of extrapyramidal effects (EPS).  |
|                    |  |
| Dosage:            | Adults age 18-65: 10mg PO<br>Pediatrics: Requires OLMC consult   |
| Supply:            | 10 mg orally dissolving tablets (ODT)  |
| Comments:          | <ol> <li>Administer tablet immediately once it is removed from the<br/>blister unit or bottle.</li> <li>Tablets disintegrate in the mouth and can be swallowed<br/>subsequently with saliva or with liquid.</li> </ol>   |

#### OXYGEN

| Oxygen                        | [EMR/EMT/AEMT/EMT-I/RN/EMT-P]  |
|-------------------------------|--|
| Class:                        | Medical gas  |
| Actions:                      | <ol> <li>Oxygen added to the inspired air raises the amount of oxygen in the blood and, therefore, the amount delivered to the tissues.</li> <li>Excessive oxygen can be harmful. Additional oxygen is not indicated if SaO2 is ≥ 95%</li> </ol> |
|                               |  |
| Indications:                  | <ol> <li>Hypoxemia or respiratory distress from any cause.</li> <li>Acute chest pain in which a myocardial infarction is<br/>suspected if SaO2 &lt; 95%.</li> </ol>  |
|                               | <ol> <li>Shock (decreased oxygenation of tissues) from any cause.</li> <li>Major Trauma if SaO2 &lt; 95%</li> <li>Carbon monoxide poisoning.</li> </ol>  |
| Contraindications:            | <ul> <li>In some patients with chronic lung disease, administration of O2 will decrease respiratory drive.</li> <li>1. Do not withhold oxygen because of this possibility.</li> <li>2. Be prepared to assist ventilation if needed.</li> </ul>   |
|                               | <ol><li>Initial O2 flow should be no greater than 2 liters per minute<br/>in these patients.</li></ol>   |
| Precautions:                  | Restlessness may be an important sign of hypoxia.<br>If the patient is not breathing adequately, the treatment of<br>choice is ventilation, not just supplemental O2.  |
| Side Effects:                 | Non humidified O2 is drying and irritating to mucous membranes.  |
| Dosage:<br>Adults & Pediatric | <ol> <li>Mild respiratory distress or patients with chronic lung<br/>disease:<br/>Low flow (1-2 L/min)</li> </ol>  |
|                               | <ol> <li>Moderate respiratory distress, or patients with SaO2 &lt; 95%<br/>on 2L via NC:<br/>Moderate flow (4-6 L/min)</li> </ol>  |
|                               | <ol> <li>Severe respiratory distress or SaO2 &lt; 90%<br/>High flow (10-15 L/Min)</li> <li>Titrate flow downward to maintain SaO2 ≥95%</li> </ol>  |
| Supply:                       | See Oxygen Flow Chart  |
| Comments:                     | Oxygen supports combustion. Use caution around flames.<br>Nasal cannulas work equally well on nose and mouth breathers.  |

### **OXYGEN FLOW CHART**

| Method  | Flow Rate                              | % Oxygen Inspired<br>(approximate) |
|---|--|------------------------------------|
| Room air  |  | 21                                 |
| Nasal Cannula (prongs)  | 1 L/min<br>2 L/min<br>8 L/min          | 24<br>28<br>40                     |
| Face Mask   | 6 L/min                                | 50 to 60                           |
| Oxygen reservoir (mask)   | 10 to 12 L/min                         | 90                                 |
| Mouth to mask   | 10 L/min<br>15 L/min<br>30 L/min       | 50<br>80<br>100                    |
| Bag/valve/mask<br>(Regulated to inflate bag<br>at proper rate.) | Room air<br>12 L/min<br>With Reservoir | 21<br>40<br>90+                    |
| Blow-by for infants   | 1 - 4 L/min                            |                                    |

# OXYMETAZOLINE HYDROCHLORIDE (Afrin)

| OXYMETAZOLINE HYD<br>(Afrin) | ROCHLORIDE [EMT-P   |
|------------------------------|---|
| Class:                       | Selective alpha 1 adrenergic receptor agonist and alpha 2 adrenergic receptor partial agonist which provides direct vasoconstriction.   |
| Actions:                     | 1. Vasoconstriction   |
| Indications:                 | 1. Epistaxis uncontrolled by direct pressure  |
| Contraindications:           | <ol> <li>Hypersensitivity/allergy</li> <li>MAOI use within the past 14 days</li> <li>Diastolic blood pressure &gt;110 mmhg</li> </ol>   |
| Pregnancy:                   | Category C  |
| Kinetics                     | <ol> <li>Onset: 1-10 minutes</li> <li>Duration: Some effects can last up to several hours</li> </ol>  |
| Side Effects:                | <ol> <li>Avoid administration into eyes which will dilate pupils.</li> <li>Temporary burning, stinging, dryness in the nose, runny nose, and sneezing may occur.</li> </ol>   |
| Dosage:                      | <ol> <li>Adult: Two sprays into each affected nostril.</li> <li>Peds: same as adult, however oxymetazoline should be<br/>avoided if child cannot follow instructions to blow their<br/>nose prior to administration.</li> </ol> |
| Supply:                      | 0.5 fl oz of nasal solution   |

# **OXYTOCIN** (Pitocin)

| Oxytocin (Pitocin) | [EMT-P]<br>Call OLMC before administration  |  |
|--------------------|---|--|
| Class:             | Hormone   |  |
| Actions:           | Increases electrical and contractile activity in uterine smooth muscle.   |  |
| Indications:       | Control of post-partum hemorrhage. Call Drug  |  |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>IM use not indicated in the presence of intrauterine<br/>pregnancy</li> </ol>  |  |
| Precautions:       | Prior to its administration, the presence of a second fetus must<br>be considered. Administration with fetus in uterus can cause<br>rupture of uterus and/or death of fetus.                                |  |
| Side Effects:      | <ol> <li>Vasodilatation</li> <li>Reflex tachycardia.</li> <li>Cardiac arrhythmias</li> </ol>  |  |
| Dosage:            | <i>Adults:</i> 10 Units (20 mg) IM<br><i>Pediatric: not applicable</i>  |  |
| Supply:            | 10 Units/ml (20mg/ml)   |  |
| Comments:          | Oxytocin can initiate or enhance rhythmic contractions at any<br>time during pregnancy, but the uterus is most sensitive at term.<br>Administration should follow delivery of placenta whenever<br>possible |  |

## ROCURONIUM (Zemuron)

| Rocuronium (Zemu   | ron) [EMT-P]   |
|--------------------|--|
| Class:             | Neuromuscular blocking agent   |
| Actions:           | 1. Non-depolarizing neuromuscular blockade   |
|                    | 2. Cholinergic receptor agonist  |
| Indications:       | 1. 2nd line paralytic for RSI  |
|                    | 2. Maintenance of paralysis after intubation   |
|                    | 3. 1st line paralytic for RSI in pregnancy   |
| Contraindications: | 1. Hypersensitivity/allergy  |
|                    | 2. Lack of ventilatory support   |
| Precautions:       | 1. Rocuronium produces paralysis, but does not alter a   |
|                    | person's level of consciousness.   |
|                    | 2. May experience resistance with $> 25\%$ TBSA burns  |
|                    | 3. May experience hypersensitivity with electrolyte disorders  |
|                    | (hyperMg, hypoK, hypoCa)   |
| Kinetics           | 1. Onset: 1 -2 min   |
| Ninetics           | 2. Duration: 30 - 60 minutes   |
|                    |  |
| Pregnancy:         | Category B   |
| Side Effects:      | 1. Apnea   |
| Olde Ellects.      | 2. Tachycardia   |
|                    |  |
| Dosage:            | Adults & Pediatric:  |
|                    | Initial Dose: 1 mg/kg IV/IO  |
|                    | Maintenance: 0.1 – 0.3 mg/kg IV/IO q 20 - 30 min   |
| Supply:            | 10 mg/ml - 10 ml vial  |
| Comments:          | 1. Dose should be calculated when possible based on ideal  |
|                    | body weight  |
|                    | 2. Should be given at initial dose the first time (1mg/kg) even if   |
|                    | the pt has already received Succinylcholine  |
|                    | 3. Paralysis in the conscious patient is very frightening,   |
|                    | therefore, sedation should be provided in any conscious or   |
|                    | • •  |
|                    | responsive patient.  |
|                    | responsive patient.<br>4. Verbal explanations should be provided to the patient during   |
|                    | <ul><li>responsive patient.</li><li>4. Verbal explanations should be provided to the patient during the procedure, even if you do not think the patient can hear</li></ul> |

### SODIUM BICARBONATE

| Sodium Bicarbonat                | e (NaHCO3) [EMT-P]  |  |
|----------------------------------|---|--|
| Class:                           | Alkalizing agent  |  |
| Actions:                         | <ol> <li>Buffers metabolic acidosis</li> <li>Increases pH</li> </ol>  |  |
| Indications:                     | <ol> <li>Cardiac arrest in a dialysis patient or suspected<br/>hyperkalemia.</li> <li>Tricyclic antidepressant overdose</li> <li>Crush injury</li> <li>Chlorine inhalation</li> </ol>   |  |
| Contraindications:               | <ol> <li>Hypersensitivity/allergy</li> <li>Hypokalemia</li> </ol>   |  |
| Precautions:                     | <ol> <li>Sodium Bicarbonate may worsen outcome in cardiac arrest.</li> <li>Providing optimum chest compressions and ventilation is<br/>best treatment of acidosis in cardiac arrest.</li> <li>May increase cerebral acidosis, especially in diabetics who<br/>are ketotic</li> </ol>                            |  |
| Side Effects:                    | Metabolic alkalosis<br>Increases sodium<br>Decreases potassium  |  |
| Dosage: Cardiac<br>Arrest/TCA OD | Adults & Pediatric: 1 mEq/kg IV/IO (1 ml/kg).<br>May repeat 0.5 mEq/kg or 1 amp until pulse is restored   |  |
| Dosage: Crush<br>Injury          | Adults : 50 mEq IV/IO slow push. May repeat 2x PRN.   |  |
| Dosage: Chlorine<br>Inhalation   | Adults & Pediatric: 2.5 ml of 8.4% nebulized.   |  |
| Supply:                          | Prefilled syringe contains 50 mEq (50 ml)   |  |
| Comments:                        | <ol> <li>Sodium Bicarbonate should be an early treatment<br/>consideration in dialysis patients in cardiac arrest.</li> <li>Common tricyclic antidepressants – Elavil ® (amitriptyline),<br/>Norpramin ® (desipramine), Pamelor ® (nortriptyline),<br/>Sinequan ® (doxepin), Tofranil ® (imipramine)</li> </ol> |  |

# SUCCINYLCHOLINE (Anectine)

| Succinylcholine (A | nectine) [EMT-P]  |  |  |  |
|--------------------|---|--|--|--|
| Class:             | Depolarizing neuromuscular blocking agent   |  |  |  |
| Actions:           | Short acting, motor nerve depolarizing, skeletal muscle relaxa  |  |  |  |
| Indications:       | Rapid sequence intubation (RSI)   |  |  |  |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Major burns and crush injuries         <ul> <li>&gt; 48 hours and &lt; 6 months old.</li> </ul> </li> <li>Stroke or spinal cord injury with profound residual deficits         <ul> <li>&gt; 48 hours and &lt; 6 months old.</li> </ul> </li> <li>Neuromuscular disease (muscular dystrophy, multiple sclerosis, etc).</li> <li>Suspected hyperkalemia such as end-stage renal disease patients who have missed dialysis.</li> </ol> |  |  |  |
| Precautions:       | Succinylcholine produces paralysis, but does not alter a person's level of consciousness.   |  |  |  |
| Side Effects:      | <ol> <li>Apnea</li> <li>Tachycardia, arrhythmia</li> <li>Fasciculations</li> </ol>  |  |  |  |
| Dosage:            | Adults: 1.5 mg/kg IV/IO push or 3 mg/kg IM<br>Pediatric: > 6 years: see Adult dosing<br><6 years: 2 mg/Kg IV/IO push or 4 mg/kg IM  |  |  |  |
| Supply:            | 200 mg/10 ml vial   |  |  |  |
| Comments:          | <ol> <li>Paralysis in the conscious patient is very frightening,<br/>therefore, sedation should be provided in any conscious or<br/>responsive patient.</li> <li>Verbal explanations should be provided to the patient during<br/>the procedure, even if you do not think the patient can hear<br/>you.</li> </ol>  |  |  |  |

#### THIAMINE

| Thiamine           | [EMT-P]  |
|--------------------|--|
| Class:             | B1 Vitamin   |
| Actions:           | Replace or supplement vitamin B1   |
| Indications:       | <ol> <li>In suspected alcoholics before or after the administration of<br/>50% dextrose.</li> <li>In suspected Wernicke's or Korsakoff's syndrome.</li> <li>In malnourished patients.</li> </ol> |
| Contraindications: | Hypersensitivity/allergy   |
| Precautions:       | Rapid IV administration has been associated with hypotension.  |
| Side Effects:      | Allergic reactions occur but are extremely rare.   |
| Dosage:            | <i>Adults:</i> 100 mg IV/IO/IM.<br><i>Pediatric:</i>   |
| Supply:            | 100 mg / 1 ml - vial<br>200 mg / 2 ml - vial   |
| Comments:          |  |

### TRANEXAMIC ACID

| Tranexamic Acid (C<br>(TXA) | yklokapron) [EMT-P]   |  |  |
|-----------------------------|---|--|--|
| Class:                      | Antifibrinolytic - Synthetic analog of the amino acid lysine  |  |  |
| Actions:                    | Reversibly binds to lysine receptor sites on plasminogen to<br>decrease the conversion of plasminogen to plasmin. This<br>reduces breakdown of fibrin and helps to stabilize clots to<br>reduce bleeding.<br>TXA also has anti-inflammatory properties.   |  |  |
| Indications:                | <ol> <li>Head trauma, moderate to severe, in patients with a GCS ≤ 12, Time of injury &lt; 2 hours</li> <li>Hemorrhagic Shock with SBP ≤ 70 mmHg, time of injury &lt; 3 hours</li> </ol>  |  |  |
| Contraindications:          | <ol> <li>Patients less than 15 years old (or weight &lt; 50 kg if age<br/>unknown)</li> <li>GCS of 3 with non-reactive pupils</li> <li>Any chest compressions (manual or mechanical)</li> <li>Patients with clinical concern for epilepsy/seizures, MI,<br/>stroke, PE, DVT, renal failure, or dialysis</li> <li>Known or suspected pregnancy</li> <li>Drowning</li> <li>Hanging</li> <li>Burns &gt; 20% TBSA</li> <li>Other procoagulant (e.g. KCENTRA) drug already<br/>administered</li> </ol> |  |  |
| Precautions:                | 1. Hypotension has been observed with rapid IV injection.   |  |  |
| Side Effects:               | Seizures<br>Nausea & vomiting<br>Chest pain   |  |  |
| Dosage:                     | Adults (Age ≥ 15, Weight > 50 kg): 2 grams IV/IO slowly over 10<br>minutes<br>Pediatric: Not indicated in patients < 15 years of age.   |  |  |
| Supply:                     | 1000 mg (1 gram) / 10 ml vial   |  |  |
| Comments:                   | <ol> <li>TXA, by causing clots to get stronger, can make MI, stroke,<br/>PE, and DVTs more challenging to manage.</li> <li>TXA is renally cleared, so its use in patients with known<br/>renal failure or dialysis should be avoided.</li> </ol>  |  |  |

# VECURONIUM (Norcuron)

| Vecuronium (Norcu  | ron) [EMT-P]   |
|--------------------|--|
| Class:             | Neuromuscular blocking agent   |
| Actions:           | Non-depolarizing neuromuscular blockade<br>Cholinergic receptor agonist  |
| Indications:       | <ol> <li>Maintenance of paralysis after intubation</li> <li>RSI</li> </ol>   |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Lack of ventilatory support</li> </ol>  |
| Precautions:       | Vecuronium produces paralysis, but does not alter a person's level of consciousness.   |
| Kinetics:          | <ol> <li>Onset: 2 - 3 min</li> <li>Duration: 20 - 35 minutes</li> </ol>  |
| Pregnancy:         | Category C   |
| Side Effects:      | <ol> <li>Apnea</li> <li>Tachycardia</li> <li>Hypersensitivity associated with histamine release<br/>(bronchospasm, flushing, urticaria, hypotension,<br/>tachycardia)</li> </ol> |
| Dosage:            | Adults: Intubation: 0.1 mg/kg IV/IO<br>Maintenance: 0.01 mg/kg IV/IO q 20 min PRN<br>Pediatric: Intubation: 0.1 mg/kg IV/IO<br>Maintenance: 0.05 mg/kg IV/IO q 60 min PRN        |
| Supply:            | 10 mg/10 ml – Vial (Comes in two vials, to be mixed)   |
| Comments:          | <ol> <li>Paralysis in the conscious patient is very frightening,<br/>therefore, sedation should be provided in any conscious or<br/>responsive patient.</li> </ol>               |
|                    | 2. Verbal explanations should be provided to the patient during the procedure, even if you do not think the patient can hear you.  |

# ZOFRAN (Ondansetron)

| Zofran (Ondansetro | n HCL) [EMT-I/RN/EMT-I   |
|--------------------|--|
| Class:             | Antiemetic   |
| Actions:           | <ol> <li>Selective antagonist of 5-HT3 serotonin receptor</li> <li>Acts centrally (DNS) and peripherally (vagus nerve)</li> </ol>  |
| Indications:       | Prevention and control of nausea and vomiting  |
| Contraindications: | <ol> <li>Hypersensitivity/allergy</li> <li>Pediatric &lt; 6 months old</li> <li>Pregnancy - category B, but recent guidelines recommend<br/>not using during pregnancy</li> </ol>  |
| Precautions:       | Zofran contains phenylalanine (caution for phenylketonurics)   |
| Side Effects:      | Headache   |
| Dosage:            | Adults: 4 mg IM or slow IV/IO (Over 2 min) or<br>>5 years old 4 mg ODT placed in mouth of conscious patient.<br>Repeat 4 mg dose in 15 minutes if no relief from first dose<br>Pediatric: >6 months old 0.1mg/kg IM/IV/IO NMT adult dose |
|                    | ODT 6 months - 5 years old 2mg half tablet   |
| Supply:            | 2 mg/ml - 2 ml Vial<br>4 mg oral dissolving tablet.  |
| Comments:          | Does not typically cause sedation<br>Peak concentration occurs 10 min after IV dose & 40 min after<br>IM   |

### **2022 MEDICATION REVISIONS**

| Drug                 | Changes   | Page # | Date of<br>Change |
|----------------------|---|--------|-------------------|
| Calcium<br>Gluconate | Increased Dosing to 3g in PEA & Asystole, Calcium Chanel<br>blocker Overdose, Hyperkalemia.<br>Increased Pediatric dose to 50 mg/kg (0.5 ml/kg) | 13     | 1/15/2022         |
| Dexamethasone        | Pediatric dose of dexamethasone decreased to 0.05 mg/kg IV/ IM/IO   | 15     | 1/15/2022         |
| Glucagon             | Decreased pediatric dosing to 0.02 mg/kg  | 27     | 1/15/2022         |
| Magnesium<br>Sulfate | Changed dosing for asthma to reflect proper administration time. Added comment for VF/VT administration.  | 37     | 1/15/2022         |
| Sodium Bicarb        | Added new dosing for chlorine inhalation.<br>Added Crush injury dosing to drug sheet.   | 49     | 1/15/2022         |